© Reuters. FILE PHOTO: A vial labeled “Sinopharm COVID-19 Vaccine” is seen in an illustration taken Jan. 16, 2022. REUTERS/Dado Ruvic/Illustration
BEIJING (Reuters) – Neutralization of certain Omicron subvariants after two doses of Sinopharm’s COVID-19 vaccine, according to a small Chinese study detailed in The Lancet Infectious Diseases The antibodies were largely undetectable, and booster shots only partially restored them.
The study comes as China has only approved locally developed COVID vaccines, including Sinopharm’s vaccine, in an effort to increase vaccination rates and maintain a “dynamic zero COVID” policy aimed at eradicating all outbreaks, while many countries have adopted a study-and-live Coexistence method virus.
The vaccine, called BBIBP-CorV, is one of two COVID vaccines approved for use in China by Sinopharm and is the main vaccine exported by the state-owned company.
Of the 25 people who received two doses of the BBIBP-CorV vaccine, the researchers published Monday.
Citing results from a cohort of 25 participants, the researchers said neutralizing activity against these sub-variants was observed in only 24-48% of subjects who received a BBIBP-CorV booster injection after two doses of the product .
According to another group of 30 subjects, the rate of getting the third shot of the vaccine produced by Chongqing Zhifei Biological Products Co., another vaccine approved for use in China, increased slightly to 30-53%.
The study did not discuss the efficacy of boosters, a rate that reflects the degree to which they reduce the risk of COVID-19 disease or death, which is typically observed in large clinical trials.